Apollo Therapeutics

Apollo Therapeutics is a Cambridge, UK-headquartered portfolio biopharmaceutical company that operates as both an investor and an integrated drug development organization. The model bridges academic research at top-tier UK universities, including Cambridge, Imperial College London, and University College London, with rapid clinical development, allowing it to acquire and advance early-stage therapeutic assets through a centralized platform. Healthcare focus is concentrated on biotech and pharma therapeutics, with an emphasis on translating university discoveries into clinical-stage programs.

Apollo Therapeutics invests at pre-seed, seed, and Series A equivalents, with deployment sizes typically in the $5M to $25M range when participating in external rounds and substantially higher when funding internal program development. Geographic activity centers on the United Kingdom, particularly within the academic spinout ecosystem of partner universities, with selective engagement in cross-border collaborations. Deal types include traditional equity investments in academic spinouts, asset acquisitions, and internal program development funded through the firm’s portfolio biopharmaceutical structure.

For founders and academic inventors, Apollo Therapeutics offers a combination of capital and integrated drug development infrastructure that is unusual within the conventional venture model. The firm is most relevant to UK academic researchers and early-stage biotech founders whose programs benefit from access to centralized clinical development, regulatory affairs, and translational research capabilities. Engagement involves substantive scientific and clinical diligence, structured asset acquisition or licensing arrangements, and ongoing operational integration with Apollo’s development platform. The firm is best suited to translational programs from partner universities and early-stage assets where founders are open to a hybrid model that combines investment with integrated development support rather than a traditional standalone company structure.